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The BNIP-2 and Cdc42GAP homology (BCH) domain is a novel regulator for Rho GTPases, but its impact on p50-Rho
GTPase-activating protein (p50RhoGAP or Cdc42GAP) in cells remains elusive. Here we show that deletion of the BCH
domain from p50RhoGAP enhanced its GAP activity and caused drastic cell rounding. Introducing constitutively active
RhoA or inactivating GAP domain blocked such effect, whereas replacing the BCH domain with endosome-targeting
SNX3 excluded requirement of endosomal localization in regulating the GAP activity. Substitution with homologous
BCH domain from Schizosaccharomyces pombe, which does not bind mammalian RhoA, also led to complete loss of
suppression. Interestingly, the p50RhoGAP BCH domain only targeted RhoA, but not Cdc42 or Rac1, and it was unable
to distinguish between GDP and the GTP-bound form of RhoA. Further mutagenesis revealed a RhoA-binding motif
(residues 85-120), which when deleted, signiﬁcantly reduced BCH inhibition on GAP-mediated cell rounding, whereas its
full suppression also required an intramolecular interaction motif (residues 169-197). Therefore, BCH domain serves as a
local modulator in cis to sequester RhoA from inactivation by the adjacent GAP domain, adding to a new paradigm for
regulating p50RhoGAP signaling.
INTRODUCTION
Rho small GTPases such as Rho, Rac, and Cdc42 play vital
roles in regulating actin cytoskeleton organization and cell
morphology during cell migration, division, apoptosis, and
tissue development. Activation of Cdc42 and Rac1 stimu-
lates the formation of ﬁlopodia and lamellipodia, respec-
tively, whereas RhoA activation stimulates the formation of
stress ﬁbers (Hall, 1998; Etienne-Manneville and Hall, 2002).
Their activities are tightly regulated by at least three major
classes of regulatory proteins, namely the guanine nucleo-
tide exchange factors (GEFs), the Rho GTPase-activating
proteins (GAPs), and the guanine nucleotide dissociation
inhibitors (GDIs; Dovas and Couchman, 2005; Bernards and
Settleman, 2007; Bos et al., 2007). Aberrant activity of Rho
and their regulators are known to affect cell proliferation
and transformation, motility, invasion, tumorigenesis, and
pathogen infection (Sahai and Marshall, 2002; Jaffe and Hall,
2005; Munter et al., 2006; Vega and Ridley, 2008). A balanced
control on Rho activity is therefore crucial for maintaining
normal physiology and understanding their mechanism of
action, and precise levels of control remains a key challenge.
RhoGAPs function as negative regulators by activating
the intrinsic Rho GTPase activity, converting the active GTP-
bound state to the inactive GDP-bound state (Moon and
Zheng, 2003; Bernards and Settleman, 2005). The human
genome encodes more than 80 RhoGAPs with distinctive
arrays of protein domain/motifs (Tcherkezian and Lamarche-
Vane, 2007). These domain/motifs could potentially act as
regulator for either their GAP activity, subcellular localization,
or connecting to various signaling networks via protein–pro-
tein interactions. These possibilities, however, await more sys-
tematic analyses. The p50RhoGAP (or Cdc42GAP) is a 50-kDa
protein that functions biochemically as a GAP for Cdc42 and
Rho (Barfod et al., 1993; Ridley et al., 1993; Lancaster et al., 1994;
Wang et al., 2005; Wang et al., 2006). Expression of p50RhoGAP
is up-regulated in Waldenstrom macroglobulinemia (Hatji-
harissi et al., 2007), whereas the expression of its homolog
BPGAP1/ARHGAP8 is up-regulated in primary colorectal tu-
mors (Johnstone et al., 2004) and cervical cancer (Song et al.,
2008). Recent studies showed that p50RhoGAP is involved in
regulating cell migration (Wang et al., 2006; Szczur et al., 2006;
Shen et al., 2008) and muscle cell differentiation (Kang et al.,
2008), whereas its homozygous knockout embryos and new-
born mice displayed reduced organ and body size, owing to
increased spontaneous Jun N-terminal kinase (JNK)-mediated
apoptosis (Wang et al., 2005, 2006, 2007). Despite being one of
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3232the earliest RhoGAPs identiﬁed where the biochemical and
structural properties of the GAP domain of p50RhoGAP are
already well deﬁned (Barrett et al., 1997; Rittinger et al., 1997;
Nassar et al., 1998), little is known on the modulation of the
GAP function inside the cells. In particular, the impact of other
protein modules such as the BNIP-2 and Cdc42GAP homology
(BCH) domain that is located N-terminus proximal to the GAP
domain remains largely undetermined. Recent studies showed
that the BCH domain contributes to autoinhibition in vitro
(Moskwa et al., 2005) and is required for its endosomal local-
ization as well as binding to Rab5 and Rab11 (Sirokma ´nyet al.,
2006).
Recent work by us and others show that the BCH domains
could regulate cell dynamics by engaging speciﬁc Rho small
GTPases, their immediate regulators, and other cellular tar-
gets. For instance, the BCH domain of BNIP-2 induces cell
protrusions by targeting Cdc42 (Low et al., 1999, 2000; Zhou
et al., 2005) and promotes muscle differentiation by coupling
the myogenic Cdo receptor signaling to p38/ MAPK ac-
tivation (Kang et al., 2008). In comparison, the homologous
BCH domain in BNIP-S targets RhoA and displaces
p50RhoGAP via its heterophilic interaction, leading to RhoA
activation, cell rounding, and apoptosis (Zhou et al., 2002,
2006). Consistently, the BCH domain of another member, the
BNIP-XL, inhibits cellular transformation by preventing on-
cogenic Lbc RhoGEF from activating RhoA after binding to
these two proteins separately (Soh and Low, 2008). Exten-
sion to this, the BCH domain of BPGAP1/ARHGAP8, a
homolog of p50RhoGAP, induces pseudopodia and cell mi-
gration by coupling to the GAP domain and proline-rich
motif (Shang et al., 2003). This BCH domain also stimulates
ERK (extracellular signal–regulated kinase) signaling,
through a yet unknown mechanism (Lua and Low, 2005).
Further, the BCH domain of BNIP-H (Caytaxin) interacts
with the kidney-type glutaminase (KGA; Buschdorf et al.,
2006) and peptidyl-prolyl isomerase Pin1 (Buschdorf et al.,
2008) to regulate neurite outgrowth.
All these ﬁndings point to the possibility that the BCH
domain of p50RhoGAP could similarly play an important
role in modulating its biological function inside the cells.
Here we present the evidence that the BCH domain on
p50RhoGAP serves as a local modulator to sequester RhoA
from being inactivated by the adjacent GAP domain. Acting
in concert with an intramolecular interaction, such seques-
tration of substrate in cis provides a novel mechanism for
regulating the local activity of p50RhoGAP toward Rho. This
could have important bearings on previously unappreciated
function of BCH or BCH-like domains in other RhoGAPs or
RhoGEFs.
MATERIALS AND METHODS
Cell Culture and Transfection
Human 293T cells were grown in RPMI-1640 medium, and HeLa cells were
grown in DMEM (high glucose) supplemented with 10% (vol/vol) fetal
bovine serum, 2 mM l-glutamine, 100 U/ml penicillin, and 100 mg/ml
streptomycin (all from Hyclone Laboratories, Logan, UT). Cells in six-well
plates were transfected with TransIT-LT1 (Mirus Bio, Madison, WI) or Lipo-
fectamine 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer’s
protocol.
Construction of Expression Plasmids
Full-length cDNA of p50RhoGAP was cloned into a hemagglutinin (HA)-
tagged, green ﬂuorescent protein (GFP)- and FLAG-tagged expression vector,
pXJ40 (Dr. E. Manser, IMCB, Singapore). FLAG-Rho-GDI plasmid was pro-
vided by Dr. Amy L. Wilson-Delfosse (Case Western Reserve University
School of Medicine; Gibson et al., 2004). Constructions used in cellular local-
ization study were as follows: yellow ﬂuorescent protein (YFP)-Golgi, red
ﬂuorescent protein–endoplasmic reticulum (RFP-ER; Clontech, Mountain
View, CA), glycosylphosphatidylinositol (GPI)-GFP and lysosomal-associated
membrane protein (Lamp1)-GFP (from A. Galmiche, Institut fu ¨r Medizinische
Strahlenkunde und Zellforschung, University of Wu ¨rzburg, Wu ¨rzburg, Ger-
many). Deletion mutants were generated by PCR using speciﬁc primers
facilitated by restriction sites. For each construct, several clones were chosen
and sequenced using the ABI PRISM BigDye Terminator Cycle Sequencing kit
(Applied Biosystems. Foster City, CA) to the entirety in both directions to
conﬁrm their identity. All plasmids were puriﬁed using Qiagen miniprep kit
(Chatsworth, CA) for use in transfection experiments. Escherichia coli strain
DH5 was used as host for propagation of the clones.
Bioinformatics
To search for putative p50RhoGAP homolog in Schizosaccharomyces pombe that
contain BCH domains, the peptide sequence of full-length p50RhoGAP was
used to carry out BLAST searches in S. pombe GeneDB using BLASTP (http://
www.genedb.org/genedb/pombe/). The percentage of similarity between S.
pombe RhoGAP and p50RhoGAP was identiﬁed by bl2seq (http://blast.
ncbi.nlm.nih.gov/bl2seq/wblast2.cgi). To identify any putative RBD/motif
(RBM) within the p50RhoGAP BCH domain, the sequence of p50RhoGAP
BCH domain (amino acids 85-217) was used for alignment with known RBD
domain of BNIP-S using the ClustalW (http://www2.ebi.ac.uk/clustalw/).
Outputs of the multiple sequence alignment were displayed with
BOXSHADE 3.21 (http://www.ch.embnet.org).
Immunoprecipitation Studies and Western Blot Analyses
Control cells or cells transfected with expression plasmids were lysed in lysis
buffer (150 mM sodium chloride, 50 mM Tris, pH 7.3, 0.25 mM EDTA, 1%
[wt/vol] sodium deoxycholate, 1% [vol/vol] Triton X-100, 0.2% sodium ﬂu-
oride, 0.1% sodium orthovanadate, and a mixture of protease inhibitors from
Roche Applied Sciences, Indianapolis, IN). Lysates were immunoprecipitated
(IPed) with anti-FLAG M2 beads (Sigma, St. Louis, MO), and the associated
proteins were separated on SDS-PAGE and probed with anti-HA (for cotrans-
fection experiments) Samples were run in SDS/PAGE gels and analyzed by
Western blotting with anti-HA (Zymed, South San Francisco, CA) or anti-
FLAG (Sigma).
Immunoﬂuorescence and Direct Fluorescence Studies
Cells were seeded on coverslips in a six-well plate and transfected with
various expression constructs for 16–20 h and then stained for immunoﬂuo-
rescence detection using confocal ﬂuorescence microscopy or directly visual-
ized for cells expressing GFP-tagged proteins as previously described (Zhou
et al., 2002). FLAG-tagged proteins were detected with monoclonal anti-FLAG
followed by Texas Red– or FITC dye–conjugated goat anti-mouse IgG (In-
vitrogen). Filamentous actin was detected by rhodamine-phalloidin (Molec-
ular Probes, Eugene, OR), and microtubule was detected by anti-tubulin
(Sigma) followed by Alexa Fluor 488–conjugated goat anti-mouse IgG (In-
vitrogen). In certain cases as speciﬁed, intensity of signal detected by confocal
microscopy was used to determine the relative expression levels of tagged
proteins across various regions of cell populations as indicated by the lines
and arrows. The images were collected using a Zeiss 510 Meta laser-scanning
microscope equipped with a 60 lens (Thornwood, NY). The detector gain
was ﬁrst optimized by sampling various regions of the coverslip and then was
ﬁxed for each speciﬁed channel. Once set, the detector gain value was kept
constant throughout the image acquisition process. As a result, signal inten-
sities from identical channels of different images could be used for quantita-
tive measurements.
Microscopic Analysis of Transferrin Uptake
HeLa cells on coverslips were incubated in extracellular H-medium (145 mM
NaCl, 5 mM KCl, 1 mM MgCl2, 0,8 mM CaCl2, 10 mM HEPES, 5 mM glucose,
pH 7.4) for 20 min at 37°C and then medium was replaced with H-medium
containing 10 g/ml Alexa 568-transferrin (Molecular Probes) for the indi-
cated times.
Rho Inhibitor Treatment
HeLa cells on coverslips were incubated with 1 g/ml the exoenzyme C3
transferase from Clostridium botulinum (Cytoskeleton, Denver, CO) for 4 h,
followed by staining with rhodamine-phalloidin (Molecular Probes) and con-
focal microscopy analysis.
RhoA activity Assays
Assays for the active (GTP-bound) form of RhoA was performed as described
previously (Zhou et al., 2006). Brieﬂy, cells were cotransfected for 24 h with
RhoA in the absence or presence of p50RhoGAP or mutants. Cells were then
lysed and subjected to pulldown assays with glutathione S-transferase (GST)
fusion of the RBD of rhotekin, which would bind and detect active RhoA in
vivo (plasmid kindly provided by Dr. Simone Schoenwaelder, Monash Uni-
versity, Australia). Bound RhoA was separated on SDS-PAGE gels and sub-
jected to Western blot analysis with the FLAG antibody.
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A total of 15 g of GST-RhoA fusion protein were preloaded with 10 mM
GDP or GTPS (Sigma) in binding buffer (25 mM NaCl, 20 mM Tris-HCl, pH
7.5, 0.1 mM DTT, and 50 mM EDTA) at 30°C for 10 min. The reaction was
stopped with MgCl2 to a ﬁnal concentration of 20 mM (Brill et al., 1996). The
beads were incubated with cell lysates at 4°C in GAP lysis buffer (50 mM
HEPES pH 7.4, 150 mM NaCl, 1.5 mM MgCl2, 5 mM EGTA, 10% glycerol, 1%
Triton X-100, 5 mM sodium orthovanadate, and a mixture of protease inhib-
itors). Samples were run in SDS-PAGE gels and analyzed by Western blotting.
RESULTS
The BCH Domain of p50RhoGAP Inhibits GAP-induced
Cell Rounding
To address the impact of other protein modules/motifs on
the cellular function of p50RhoGAP, human cervical epithe-
lial HeLa cells were transfected with either the wild type or
its three mutants, namely a PRR mutant lacking the pro-
line-rich region (amino acids 218-258), the NBCH (N-termi-
nus containing the BCH domain, but lacking proline region;
amino acids 1–217) or the PGAP (proline-containing carboxyl
end, harboring the GAP domain; amino acids 218-439; Figure
1A). Their effects on cell morphology were compared and
quantiﬁed by indirect immunoﬂuorescence microscopy after
costaining with anti-tubulin antibodies to visualize microtu-
bules (Figure 1B). Figure 1C shows that only 15% of the cells
transfected with full-length p50RhoGAP appeared round,
whereas the majority of them still remained cuboidal or began
to show cell retraction/shrinkage. In contrast, 90% of the cells
transfected with PGAP already exhibited drastic cell round-
ing as shown in Figure 1B. Such effects on morphology were
not due to variations in the protein expression because all
their protein levels were identical (Supplementary Figure
S1). To further examine the threshold of regulation by the
GAP domain, we analyzed its expression levels and showed
that even at very low expression levels, the PGAP domain
Figure 1. The BCH domain of p50RhoGAP inhibits GAP-induced cell rounding. (A) Schematic diagram of p50RhoGAP and its mutants:
N-terminus without GAP domain (NBCH, amino acids 1-217), C-terminus without BCH domain (PGAP, amino acids 218-439), and a mutant
without the proline-rich region, PPR (PPR, 218-258). (B) HeLa cells were transfected with plasmids encoding FLAG-tagged full-length
p50RhoGAP, NBCH, PGAP, or PPR mutants. Cells were then ﬁxed after 16–20 h and subjected to confocal ﬂuorescence microscopy as
described in Materials and Methods. Morphological changes and cytoskeletal rearrangements were revealed by indirect immunostaining with
Alexa Fluor 488–conjugated goat anti-mouse IgG against anti-tubulin for microtubules and with FLAG antibody for expressed FLAG-tagged
proteins. (C) For quantitative analysis, the ratio of cuboidal, protrusion/shrinkage, and round cells was scored with at least 150 transfected
cells counted per sample per experiment. Data are means  SD (n  3).
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trast, p50RhoGAP would increase the extents of cell round-
ing only when it was highly expressed (Supplementary Fig-
ure S2). This observation indicates that the N-terminal
NBCH region could exert an inhibitory effect toward the
otherwise very potent activity of the C-terminal GAP do-
main. The inhibitory effect was not due to the proline-con-
taining sequence because cells expressing the PRR mutant
still displayed normal morphology. In comparison, the
presence of the BCH domain in NBCH-transfected cells
did not alter the overall cell morphology. This effect is
different from the potent cell-rounding effect induced by
the BCH domain of BNIP-S (Zhou et al., 2006), which was
localized in punctate structures (Supplementary Figure
S3), whereas p50RhoGAP BCH domain was predomi-
nantly localized to cell periphery (see Figure 2D). These
results therefore support the speciﬁc and novel role of the
adjacent BCH domain in suppressing the GAP activity of
p50RhoGAP inside the cells.
The GAP Domain of p50RhoGAP Induces Cell Rounding
by Inactivating RhoA
To explore the molecular basis underlying the new inhibi-
tory role of the BCH domain in p50RhoGAP, we needed to
ﬁrst establish the basis of cell rounding induced by the GAP
domain. Previous studies showed that p50RhoGAP could
interact with Cdc42 and RhoA in vitro (Barfod et al., 1993;
Lancaster et al., 1994) and also inactivated these two Rho
GTPases in cells (Ridley et al., 1993; Wang et al., 2005; Wang
et al., 2006). In HeLa cells, it has been reported that
p50RhoGAP targets RhoA, but not Cdc42 (Moskwa et al.,
2005; Sirokma ´nyet al., 2006). Interestingly, once treated with
Rho inhibitor C3 transferase from C. botulinum, HeLa cells
displayed similar cytoskeleton collapse and cell rounding as
induced by GAP domain (Figure 2A). This observation
prompted us to examine whether cell rounding and cy-
toskeleton disruption induced by the GAP domain of
p50RhoGAP, and its regulation by the adjacent BCH domain
as shown above, would involve RhoA inactivation. First, we
examined the interactions between p50RhoGAP and RhoA,
Cdc42, or Rac1 in HeLa cells. These Rho GTPases were
expressed in the same HA-epitope to allow direct compari-
son of their binding afﬁnity. Figure 2B shows that RhoA
but not Cdc42 or Rac1 was preferentially coIPed with
p50RhoGAP. Next, RhoA activity assays also showed a
marked reduction in the level of active RhoA in the presence
of the single GAP domain when compared with full-length
p50RhoGAP (Figure 2C and Supplementary Figure S4). Con-
sistent with these biochemical data were the confocal imag-
ing analyses for the impact of the full-length, NBCH and
PGAP fragments on RhoA-induced stress ﬁbers and cell
rounding (Figure 2D). Here, expression of the PGAP frag-
ment without the BCH domain led to extensive cell round-
ing accompanied by a total collapse of the F-actin. In strong
contrast, the full-length p50RhoGAP or the NBCH did not
affect the formation of stress ﬁbers induced by RhoA despite
that the cell periphery projections in RhoA-expressing cells
were abolished in the presence of NBCH (indicated by yel-
low boxes). The cell rounding induced by GAP domain
could be blocked by coexpressing the constitutive active
RhoA-G14V with PGAP with full restoration of stress ﬁbers
(Figure 2E; comparing yellow boxes), indicating that cell
rounding indeed required inactivation of RhoA.
To ascertain that such RhoA inactivation was a direct
effect from the GAP activity of p50RhoGAP and not via
other indirect pathways, we went on to nullify the enzy-
matic function of the GAP domain by mutating several key
amino acids; these include the “invariant” arginine ﬁnger
R282, which is critical as a catalytic residue in trans (Leonard
et al., 1998), the secondary arginine R283 (Leonard et al.,
1998), and the highly conserved asparagine N391 for stabi-
lizing the Rho effector loop (Rittinger et al., 1997). PGAP
mutants carrying R282A, N391V, R282A/R283A, R282A/
N391V, and R282A/R283A/N391V were each expressed in
HeLa cells and showed that cells expressing either single-
point mutants (R282A, N391V) or double-points mutants
(R282A/R283A, R282A/N391V) still exhibited drastic cell
rounding (Figure 3A). Only cells expressing the triple-point
mutant R282A/R283A/N391V displayed the regular cuboi-
dal morphology indicating the complete loss of its GAP
activity (Figure 3A), as evidenced by the Rho activity assay
(Figure 3B) and its inability to resolve RhoA-induced stress
ﬁbers (Supplementary Figure S5).
These results therefore conﬁrm that p50RhoGAP interacts
with and inactivates RhoA in the cells, resulting in extensive
cytoskeletal collapse and cell rounding in a process medi-
ated by the catalytic GAP domain. Most signiﬁcantly, the
adjacent BCH domain could suppress such a potent GAP
activity.
Suppression of p50RhoGAP Activity Does Not Require Its
Endosomal Localization or Intramolecular Interaction
Alone
It was recently reported that the BCH domain, which shares
very limited sequence homology to the Sec14p domain, is
required for the intramolecular interaction with the GAP
domain (Moskwa et al., 2005) and the endosomal localization
of p50RhoGAP (Sirokma ´ny et al., 2006). These observations
offer two potential mechanisms for BCH domain-mediated
GAP inhibition. First, the two previously reported intramo-
lecular interaction regions (IIR 1: 1–48 and IIR 2: 169–197,
Moskwa et al., 2005) could sterically inhibit GAP function via
the BCH–GAP intramolecular interaction. Figure 4 shows
that expression of two mutants lacking these two intramo-
lecular interaction regions alone (FL53 and FL151-217) dis-
played no signiﬁcant effect on cell morphology or actin
network, indicating that such intramolecular interactions
alone did not directly suppress the GAP function in cells.
However, one of the motifs, IIR 2, turned out to augment the
inhibitory effect of BCH domain as shown in our further
analyses (see later).
Alternatively, the BCH domain could restrict p50RhoGAP
to speciﬁc cellular environment where other extrinsic factors
could directly or indirectly inhibit its function. To examine
this further, the endosomal marker Alexa-568–coupled
transferrin and a series of cellular organelle markers were
used to monitor the subcellular distribution of p50RhoGAP.
Supplementary Figure S6A shows the partial colocalization
of p50RhoGAP with transferring-positive endosomes, but
not with LAMP1 (lysosome), mitotracker (mitochondria),
and the GPI-anchored protein compartment, indicating that
a fraction of this GAP was localized in endosomes. Next, we
substituted the BCH domain of p50RhoGAP with a speciﬁc
endosomal module from the endosome localizing protein,
sorting nexin3 (SNX3; Xu et al., 2001). Should an extrinsic
factor be required to inhibit the GAP function there, this
substitution would retain the suppression effect. Interest-
ingly, this SNX3-PGAP mutant still caused cell rounding
(Supplementary Figure S6B), although the hybrid protein
still displayed endosomal localization (Supplementary Fig-
ure S6C; arrows). This result demonstrates that the endoso-
mal localization of p50RhoGAP per se is not responsible for
bringing about extrinsic factors to inhibit its GAP function
there.
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inhibitor C3 Transferase followed by rhodamine-conjugated phalloidin staining and confocal ﬂuorescence microscopy analysis. (B) Cells were
transfected with FLAG-p50RhoGAP in the presence or absence of HA-tagged expression constructs of Cdc42, Rac1, and RhoA. Lysates were
immunoprecipitated (IP) with anti-FLAG beads, and the associated proteins were separated on SDS-PAGE, blotted, and probed with HA
antibody. Expression of FLAG-p50RhoGAP and HA-tagged Cdc42, Rac1, and RhoA were veriﬁed by Western blot analyses for the whole cell
lysates (WCL) using anti-FLAG (third panel) and anti-HA (bottom panel), respectively. The bound GTPase was detected by anti-HA (top
panel), and equal loading of IP beads were veriﬁed by anti-FLAG (second panel). (C) To determine the Rho GTPase activity, HeLa cells were
transfected with FLAG-tagged wild-type RhoA in the presence and absence of HA-tagged p50RhoGAP, NBCH, or PGAP mutants. Cell were
lysed and incubated with GST fusion of the Rho-binding domain of rhotekin immobilized on beads as described in Materials and Methods
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Rho-binding Proﬁle
The data presented so far suggest that the intrinsic property
of BCH domain itself is critical in inhibiting the RhoGAP
activity. Because our earlier work had demonstrated that
various BCH domains could target small GTPases, it is
conceivable that the BCH domain of p50RhoGAP could also
bind RhoA, consequently preventing the GAP domain from
acting on the same target. To test this hypothesis, we ﬁrst
determined the interaction between the NBCH fragment
Figure 2 (cont). Bound active RhoA were resolved on SDS-PAGE and detected by immunoblotting with FLAG-antibody (top panel). Equal
loading of GST fusion proteins is shown in the second panel. (D) HeLa cells were transfected with plasmids encoding HA-RhoA alone or with
FLAG-tagged full-length p50RhoGAP, PGAP, or NBCH mutants. Cells were then ﬁxed after 20 h and subjected to confocal ﬂuorescence
microscopy as described in Materials and Methods The actin ﬁlaments were detected by direct costaining with rhodamine-conjugated
phalloidin. (E) HeLa cells were cotransfected with HA-tagged PGAP mutant and wild-type or constitutively active RhoA-G14V. Cells were
then ﬁxed and images analyzed by confocal ﬂuorescence microscopy after direct staining with rhodamine-conjugated phalloidin for actin
ﬁlaments.
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5A shows that both full-length p50RhoGAP and NBCH
could interact with RhoA whereas binding of RhoA to PGAP
remained undetectable despite the potent GAP activity to-
ward RhoA (Figure 2C). This was attributed to their high
turnover and transient nature of enzyme-substrate relation-
ship. Moreover, similar to the full-length p50RhoGAP (Fig-
ure 2B), the BCH domain speciﬁcally interacted with RhoA,
but not with Cdc42 or Rac1 (Figure 5B).
The presence of BCH domain and RhoGAP domain as two
Rho-targeting domain in tandem raises an interesting issue
as to how Rho, as their common substrate, would be recog-
nized and how the dynamic nature of the complex regu-
lated. To gain some insights to this process, we examined
how the BCH domain of p50RhoGAP could differentiate
between the GTP-bound active Rho from the GDP-bound
inactive Rho. To determine if the binding toward RhoA is
nucleotide-dependent, GST-RhoA was unloaded or loaded
Figure 3. Three essential residues for GAP domain in inducing
cell rounding. (A) HeLa cells were transfected with HA-tagged
PGAP or the various mutants indicated, ﬁxed after 20 h, and
subjected to confocal ﬂuorescence microscopy with anti-HA and
Alexa Fluor 488 dye–conjugated goat anti-rabbit IgG as de-
scribed in Materials and Methods. (B) To determine the Rho
GTPase activity, HeLa cells were transfected with FLAG-tagged
RhoA alone or with various HA-tagged PGAP or its various
mutants. Cell were lysed and incubated with GST fusion of the
Rho-binding domain of rhotekin immobilized on beads as de-
scribed in Materials and Methods. Bound active RhoA were re-
solved on SDS-PAGE and detected by immunoblotting with
FLAG-antibody (top panel). Equal loading of GST fusion pro-
teins is shown in the second panel.
Figure 4. Intramolecular interaction alone does not regulate GAP activity. HeLa cells were transfected with FLAG-tagged-FL53 or
FL151-217 mutants and subjected to confocal ﬂuorescence microscopy after direct staining with rhodamine-conjugated phalloidin for actin
ﬁlaments.
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incubated with lysates expressing NBCH in a series of par-
allel experiments using two different controls (i.e., the PGAP
fragment of p50RhoGAP which is expected to recognize the
GTP-bound form; Barrett et al., 1997; Rittinger et al., 1997;
Nassar et al., 1998) and the Rho-GDI, which recognizes Rho
independently of the nucleotides (Hancock and Hall, 1993;
Zalcman et al., 1996; Nomanbhoy and Cerione, 1996). Unlike
PGAP region that preferentially bound GTPS-RhoA, the
BCH domain shows no preference for the nucleotide-free,
GDP-, or GTPS-bound form of RhoA (Figure 5C), a proﬁle
shared also by the Rho-GDI.
Taken together, all these data demonstrate that the BCH
and GAP domains, despite binding to a common target,
display unique binding characteristics that could be of im-
portance in regulating the function of Rho inside the cells.
The BCH-like Domain of S. pombe That Does Not Bind
Mammalian RhoA Cannot Functionally Substitute for the
BCH Domain of p50RhoGAP
To further test the hypothesis that RhoA-binding ability was
indeed responsible for the inhibitory effect, we ﬁrst substituted
the p50RhoGAP BCH domain with the homologous BCH do-
main of the RhoGAP from S. pombe. The yeast BCH-like do-
main was chosen because the evolutionary relationship be-
tween human and yeast is distant enough that the yeast BCH
domain is unable to bind human RhoA. Bioinformatics analy-
sis shows that the S. pombe homolog shares 43% similarity with
p50RhoGAP full length and 51% similarity in their BCH do-
mains (Supplementary Figure S7A). The S. pombe BCH domain
was fused with the PGAP fragment (pBCHhPG; Supplemen-
tary Figure S7B) and lost the RhoA-binding ability as deter-
mined by coIP study (Supplementary Figure S7C). Once intro-
duced into HeLa cells, pBCHhPG mutant was able to inactivate
RhoA (Supplementary Figure S7D) and induced drastic cell
rounding (Supplementary Figure S7B), similar to the earlier
observation by PGAP that had its entire adjacent BCH domain
removed. This result indicates that binding of RhoA and there-
fore its sequestration could play a vital role in the suppression
of GAP-induced cell rounding.
The BCH Domain of p50RhoGAP Contains a Novel
Rho-binding Motif
To further establish the “substrate sequestration” model, a
p50RhoGAP mutant lacking only the RhoA-binding ability
in its BCH domain is therefore required. To help identify
such potential RhoA-binding sites, analysis of primary se-
quences of p50RhoGAP BCH domain with another RhoA-
binding BCH domain from BNIP-S (Zhou et al., 2002) was
ﬁrst carried out. Such analysis revealed a putative RBM at
the positions 85–125 of p50RhoGAP BCH domain (Figure
6A). Based on the secondary structure prediction, this BCH
domain was further subdivided into four subregions (i.e.,
regions A, residues 85-120, putative RBM; B, residues 121-
150; C, residues 151-180; and D, residues 181-217). Next, two
NBCH mutants lacking the putative RBM (85-120, 85-150)
were generated. Four other constructs (121-150, 121-180,
151-180, and 181-217) with deletion regions falling out-
side the putative RBM yet covering the other segments of the
entire p50RhoGAP BCH domain were also prepared (Figure
6B). Cells were cotransfected with an HA-RhoA expression
plasmid together with the FLAG-tagged NBCH wild type or
Figure 5. The BCH domain of p50RhoGAP displays distinctive RhoA binding proﬁle. (A) HEK293T cells were transfected with plasmid
encoding HA-RhoA alone or with FLAG-p50RhoGAP, NBCH or PGAP. Lysates were immunoprecipitated (IP) with anti-FLAG beads, and
the associated proteins were detected with HA antibody (top panel). Expression of FLAG-tagged proteins and HA-RhoA were veriﬁed by
Western blot analyses by anti-FLAG (third panel) and anti-HA (bottom panel), respectively. Equal loading of IP beads were veriﬁed by
anti-FLAG (second panel). (B) Cells were transfected with plasmid encoding FLAG-NBCH in the presence or absence of HA-tagged Cdc42,
Rac1, and RhoA. Lysates were immunoprecipitated (IP) with anti-FLAG beads, and the associated proteins were separated on SDS-PAGE,
and probed with HA antibody (top panel). Expression of FLAG-tagged NBCH and HA-tagged GTPases were veriﬁed by Western blot
analyses using anti-FLAG (third panel) and anti-HA (bottom panel), respectively. Equal loading of IP beads were veriﬁed by anti-FLAG
(second panel). (C) HEK293T lysates expressing FLAG-NBCH, PGAP fragments or Rho-GDI were incubated with unloaded GST-RhoA,
GST-RhoA preloaded with GDP, or GTPS as described in Materials and Methods. Bound proteins and whole cell lysates (WCL) input were
analyzed with anti-FLAG and equal loading of GST beads veriﬁed by amido black staining.
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showed that the two mutants (A and AB) lacking the
predicted RBM led to severe loss of binding to RhoA (Figure
6C). Other mutants, however, still retained their binding to
RhoA. As a further control for their structural integrity,
these two non-RhoA-binding mutants still retained their
ability to form the homophilic interaction (Supplementary
Figure S8). The region spanning amino acid residues 85-120
of the BCH domain therefore contains a novel RhoA-binding
motif.
Full Suppression of p50RhoGAP Activity by BCH Domain
Requires RhoA Sequestration Acting in Concert with Its
Intramolecular Interaction
Next, we examined whether the p50RhoGAP lacking the
RBM in the BCH domain could indeed lead to loss of its
suppression effect on GAP activity. A series of FLAG-tagged
p50RhoGAP truncation mutants were generated and their
effect on cell rounding were then determined (Figure 7A).
Among these mutants, FLBCH contains an entire intact BCH
domain (with only the N-terminal amino acid 1-84 re-
moved), whereas FL121 and FL161 mutants have their RBM
removed. All these three mutants lack a previously identi-
ﬁed IIR 1 (1-48, Moskwa et al., 2005), but they still retain IIR
2 (169–197, Moskwa et al., 2005). To examine whether RhoA
sequestration was the only mechanism that the BCH domain
employs to inhibit GAP activity, a further deletion with an
impaired IIR 2 was also included, designated FL181. HeLa
cells transfected with either the wild type or the mutant with
an intact BCH domain (FLBCH) displayed normal cuboidal
morphology (Figure 7, A and B), indicating strong inhibition
of the GAP activity. Once the RBM was removed, as seen for
Figure 6. Identiﬁcation of a RhoA-binding motif within the BCH domain of p50RhoGAP. (A) Multiple sequence alignments of BCH domains from
Homo sapiens BNIP-S (AY078983) and p50RhoGAP/Cdc42GAP (Q07960) using ClustalW and formatted using BOXSHADE. Identical residues are
shaded black whereas similar or conserved ones are in gray. The region corresponding to the previously described Rho-binding motif in BNIP-S
(Zhou et al., 2006) was underlined. (B) Schematic diagram of NBCH domain and its mutants. (C) Cells were cotransfected with HA-tagged RhoA
and FLAG-tagged NBCH wild type or mutants as depicted in Figure 6B. Lysates were immunoprecipitated (IP) with anti-FLAG beads, and the
associated proteins were separated on SDS-PAGE, blotted, and probed with HA antibody. Expression of FLAG-NBCH constructs and HA- RhoA
were veriﬁed by Western blot analyses of the whole cell lysates (WCL) using anti-FLAG (third panel) and anti-HA (bottom panel), respectively.
The bound RhoA was detected by anti-HA (top panel), and equal loading of IP beads were veriﬁed by anti-FLAG (second panel).
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reduced. In FL121 and FL161 mutants (where RBM was
absent), close to 60–70% of the transfected cells displayed
drastic cell protrusion and rounding when compared with
the FLBCH (20%) or the wild type (30%). This data demon-
strated that the RhoA-binding ability indeed plays an im-
portant role in suppression of the GAP activity. However,
the impact of two non-RhoA-binding mutants (FL121 and
FL161) was not as potent as that from PGAP (near 100%),
which had the entire BCH domain removed. In contrast,
FL181, which had lost its RhoA-binding and both IIRs, led to
a similar cell rounding effect (95%) as did PGAP. Consis-
tently, RBD assay shows enhanced GAP activity of FL121
compared with wild-type p50RhoGAP, whereas FL181 con-
ferred the same maximal GAP activity as did PGAP (Figure
7C). To ensure that these effects on morphology were not
due to variations in the protein expression, their respective
expression levels were veriﬁed to be the same by Western
Figure 7. The BCH domain of p50RhoGAP inhibits the adjacent GAP function by sequestering RhoA. (A) HeLa cells were transfected
for 20 h with FLAG-tagged p50RhoGAP wild type and mutants including FLBCH, FL121, FL161, FL181, or PGAP. Cells were then ﬁxed
and incubated with FLAG monoclonal antibodies, followed by Alexa Fluor 488-conjugated goat anti-mouse IgG. Cell morphology was
monitored by direct staining with rhodamine-conjugated phalloidin for actin ﬁlaments. (B) For quantitative analysis, the ratio of
cuboidal, protrusion/shrinkage, and round cells was scored and at least 150 transfected cells were counted per sample per experiment.
Data are means  SD (n  3). (C) Cells were transfected with FLAG-tagged p50RhoGAP full-length, FL121, FL181, or PGAP
in the presence of HA-RhoA. After 20 h, cell were lysed and incubated with GST fusion of the Rho-binding domain of rhotekin-
immobilized on beads, in order to assess the impacts of p50RhoGAP and the mutants in regulating RhoA activity as described in
Materials and Methods. Bound GTPases were resolved on SDS-PAGE and detected by immunoblotting with HA-antibody (top panel).
Equal loading of GST fusion proteins is shown in the second panel. (D) HeLa cells were cotransfected with HA-tagged PGAP and
FLAG-tagged-NBCH or BCH domain. Cells were then ﬁxed and analyzed with confocal ﬂuorescence microscopy as described in
Materials and Methods.
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or by confocal microscopy analyses (Supplementary Figures
S10). This result therefore indicates that both RhoA seques-
tration and intramolecular interaction (via IIR 2) act in con-
cert to allow the BCH domain to fully suppress the activity
of the adjacent GAP domain.
It is intriguing that, despite having the ability to bind
RhoA, the BCH domain alone did not affect the overall cell
morphology (although it did abolish periphery projections
induced by Rho despite retaining stress ﬁber; see discussion
later) and the Rho activity. However, when present with the
GAP domain, this BCH domain greatly suppresses the ad-
jacent GAP activity by sequestering RhoA and forming an
intramolecular interaction. This phenomenon raises further
speculation that the regulatory function of this BCH domain
is physically coupled to the GAP domain. Consistently, co-
expression of either BCH or NBCH domain with the GAP
domain as two separate entities (in trans) failed to suppress
any of the GAP-mediated cell rounding (Figure 7D). Such
requirement for its physical linkage in cis would suggest a
need for speciﬁc conformation or/and microenvironment to
modulate the local pools of RhoA.
Taken together, we have demonstrated that the BCH
domain of p50RhoGAP acts as a novel local modulator of
GAP activity by engaging a speciﬁc RhoA-binding motif
that exhibits a unique binding proﬁle in order to sequester
RhoA and prevent it from being inactivated by the adja-
cent RhoGAP domain. Furthermore, we show that such
inhibition could work in concert with an IIS distal to
RhoA-binding, thus adding a new paradigm of regulating
p50RhoGAP and Rho signaling.
DISCUSSION
BCH Domain as a Regulatory Module for GTPases
Signaling
Despite having a highly conserved enzymatic GAP module
that inactivates Rho, many RhoGAPs exist to regulate di-
verse and complex cellular processes. This is mainly attrib-
uted to the ability of one RhoGAP to target more than one
member of Rho GTPases and the potential of multiple
RhoGAPs to regulate one single Rho. Furthermore, the ex-
istence of dynamic arrays of multiple domains in different
RhoGAPs could potentially add to the repertoire of their
Figure 7. Continued.
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interacting partners and cross-talks, directing to speciﬁc
compartments or/and undergoing posttranslational modiﬁ-
cations. RhoGAPs confer broad substrate speciﬁcity toward
Rho. For example, p200RhoGAP stimulates the GTPase ac-
tivities of both Rac1 and RhoA in vitro and in vivo (Moon et
al., 2003) whereas hCdGAP targets Cdc42 and Rac1 (Tch-
erkezian et al., 2006). Similarly, p50RhoGAP also acts on
Cdc42 and Rho in vitro (Barfod et al., 1993; Lancaster et al.,
1994), whereas the loss of p50RhoGAP expression is linked
to activation of Cdc42 inside the cells (Wang et al., 2005,
2006; Kang et al., 2008). Here, we show that p50RhoGAP
instead binds preferentially to RhoA and not to Cdc42 in
HeLa cells, primarily through its BCH domain. Recent stud-
ies by Sirokma ´nyet al. (2006) also showed that in HeLa cells,
p50RhoGAP has no effect on the distribution of Cdc42 and
that both proteins show no colocalization. We believe that
such variation in the substrate recognition is likely due to
different cell types and different subcellular environments,
thus providing greater functional plasticity and regulation
for Rho signaling. In all cases, however, there is still a lack
of evidence on how its activity could be regulated at the
molecular level. By domain deletion, swapping, delineat-
ing the key RhoA-binding region within the BCH domain,
and linking their interaction to cell morphological changes, we
have revealed a cryptic role of the N-terminal BCH do-
main toward the activity of the adjacent GAP domain in
p50RhoGAP, offering new insights to the regulation of
Rho signaling by the multidomain RhoGAPs. Further, its
preference for RhoA but not Cdc42 or Rac1 could provide
a selective regulation of the GAP activity for RhoA, at
least in the HeLa cells.
We have recently established the roles of BNIP-2 BCH
domain in conferring Cdc42-dependent cell protrusions
(Zhou et al., 2005) and p38-mediated pathways (Kang et al.,
2008) and the ability of the BCH domains of BNIP-S and
BNIP-XL in trans to counteract suppression of RhoA by
p50RhoGAP (Zhou et al., 2006) and to counteract activation
of RhoA by Lbc RhoGEF (Soh and Low, 2008), respectively.
Unlike the above scenarios where regulation occurs via in-
teraction of two separate molecules, our current ﬁndings
provide the ﬁrst evidence that BCH domain acts as an im-
portant regulatory switch for the GAP function when
present together on the same protein.
Our results show that upon removal of the BCH domain
the GAP domain conferred much enhanced activity toward
RhoA, although no RhoA was detectable in the immmuno-
complex of GAP. This is attributed to their high turnover
and transient nature of enzyme–substrate interaction, which
is also generally observed in other reactions such as kinases
and their substrates. Consistently, the active GAP promotes
extensive cell rounding that could only be abrogated when
the triple catalytic mutant was introduced or blocked by
constitutive active RhoG14V. In contrast, the BCH domain
did not affect the Rho activity when present alone despite its
strong binding to RhoA, and no impact on the overall cell
morphology was observed. However, it is worth noting that
this BCH domain alone did suppress RhoA-induced cellular
projections, leading to a more cuboidal structure that still
retained intact stress ﬁbers. These data imply that although
NBCH domain does not directly affect the RhoA activity
per se, it could still modulate the impact of RhoA signal-
ing, probably by indirectly interfering with some of its
downstream effectors. However, when BCH domain was
present with the GAP domain, the binding of full-length
p50RhoGAP with Rho became evident but the GAP activ-
ity toward Rho was signiﬁcantly reduced. Consequently,
the cells did not round up.
Interestingly, despite sharing the same preference for
RhoA as the BCH domains of BNIP-S and BNIP-XL and the
ability to interact with both GDP- or GTP-bound forms of
Rho, the BCH domain of p50RhoGAP, when present alone,
does not signiﬁcantly affect cell morphology; however,
when present with the GAP domain, it acts as an potent
inhibitor of GAP in cis. This highlights the absolute require-
ment for the p50RhoGAP BCH to be present with the GAP
in totality in speciﬁc microenvironment or/and requiring
certain conformation in order to exert its impact on local
pools of RhoA, thus further demonstrating the versatility of
different BCH domains in regulating Rho signaling in vari-
ous subcellular environments. Consistent with this, its dual
ability to interact with GDP- or GTP-bound form of Rho
would permit a dynamic cross-regulation such that captur-
ing the GTP-bound Rho would ensure no inactivation by
GAP, whereas capturing GDP-Rho could prevent activation
by GEF. Depending on which and when such GAP and
GEFs are being activated, the overall outcome would be
different or would be neutralized. This could also explain
why overexpression of BCH domain alone does not readily
lead to any noticeable effects in cells. However, it remains
unclear at the molecular level as to how the binding of BCH
domain to Rho would be different from other Rho-binding
modules such as GAP, GEF, and GDI as well as other
effector molecules. It is also worth noting that besides
p50RhoGAP and its homolog BPGAP1, several BCH-like
domains are also present in cis with the GEF domain in Dbl,
Duo, and Trio RhoGEFs and also in neuroﬁbromatosis type
1 (NF1) RasGAP (Zhou and Low, unpublished data). It
remains an exciting prospect to determine whether these
BCH domains could act to modulate the local GTPases ac-
tivity by a similar or distinct mechanism from that shown by
p50RhoGAP.
How Could RhoA Sequestration Be Reversed?
Our data showed that the BCH domain of p50RhoGAP
could serve as a local sink to sequester RhoA and subse-
quently prevent it from inactivation. This could explain why
previous knockout (Wang et al., 2005, 2006) and our shRNA
studies (Supplementary Figure S11) show no signiﬁcant el-
evated level of stress ﬁbers. Thus, it remain to be seen how
upon relief of sequestration, the substrate could in turn
become available for the adjacent GAP domain, and vice
versa. Their unique proﬁles in recognizing the substrate
might hold keys to understanding some of the complex
nature of regulation. For example, could there be a dynamic
conformational switch that allows transient transfer of the
substrate between the two domains? How would the cycling
of GTP/GDP-bound state of Rho determine whether they
would be sequestered by BCH domain, released from there,
and subjected to activation by GEF or inactivation by GAP?
Although the ability of BCH domain to capture either the
GDP-bound or GTP-bound form as discussed above could
provide a dynamic dual regulation for RhoGAP as well as
RhoGEF functions, it is possible that the exchange of nucle-
otides of RhoA might regulate the activity of p50RhoGAP.
For example, p50RhoGAP could be inhibited when bound to
GDP-RhoA, but upon RhoA activation by a nearby RhoGEF
and facilitated by BCH domain, the RhoA is released to
allow the catalytic activation of p50RhoGAP. This hypothe-
sis was supported by our new ﬁnding that p50RhoGAP
could indeed interact with p115RhoGEF through its BCH
domain (Supplementary Figure S12). Because BCH does not
directly increase active Rho level by itself and that BCH
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that this domain could serve as a scaffold that link
p115RhoGEF to other unknown biological functions or/and
possibly be involved in reversing RhoA sequestration, al-
lowing Rho to be inactivated by the adjacent GAP domain.
This adds to the versatility of BCH domain in regulating not
just directly on Rho but also the RhoGAP and RhoGEF, with
the latter also observed for another BCH-containing member,
BNIP-XL that targets the DH-PH domain of Lbc RhoGEF (Soh
and Low, 2008).
The fact that coexpression of individual BCH domain with
full-length p50RhoGAP could not enhance cell rounding
and GAP activity also suggests that homophilic interaction
between BCH domains of p50RhoGAP does not inhibit its
ability to sequester RhoA. On the other hand, ﬁndings that
phospholipids have the ability to “switch” the GTPase sub-
strate preference of p190RhoGAP provide an attractive pos-
sibility (Ligeti et al., 2004; Ligeti and Settleman, 2006). The
limited degree of homology between the BCH domain and
the Sec-14p domain that functions in phosphatidylinositol
transfer (Mousley et al., 2007; Schaaf et al., 2008) suggests
that the BCH domain of p50RhoGAP could possess lipid-
binding property and p50RhoGAP activity could be modu-
lated via a lipid-dependant mechanism. On the other hand,
it was previously proposed that Rac could relieve the in-
tramolecular interaction of p50RhoGAP, albeit in vitro, by
binding to the extreme N terminus (Moskwa et al., 2005).
Similarly, it binds and activates p190B RhoGAP in cells
(Bustos et al., 2008). However, based on an IP study, we did
not readily detect any Rac1-p50RhoGAP interaction in HeLa
cells, raising the possibility that other forms of Rac (e.g.,
Rac2 and Rac3) or other closely related Rho GTPases could
instead be involved in reversing the sequestration by dis-
placing RhoA from the BCH domain. However, to achieve
that, such GTPases must also interact with similar motif in
the BCH domain. All these possibilities await further de-
tailed investigation.
Concerted Regulatory Mechanisms for Modulating
p50RhoGAP Activity
Intramolecular interaction plays critical roles in regulating
Rho GTPase regulator proteins, including the RhoGEF (e.g.,
p115RhoGEF, Vav, proto-Dbl, and Ect2; Hart et al., 1998;
Aghazadeh et al., 2000; Bi et al., 2001; Kim et al., 2005) and
RhoGAP (e.g., 120RasGAP, CdGAP, oligophrenin-1, and
GGAP; Drugan et al., 2000; Jenna et al., 2002; Fauchereau et
al., 2003; Xia et al., 2003). In most cases, certain protein–
protein interaction domains are critical for masking their
catalytic domains (Jenna et al., 2002; Xia et al., 2003; Yohe et
al., 2007). It has previously been reported that the N-termi-
nus of p50RhoGAP, including part of the BCH domain (i.e.,
IIR 2), could mask the GAP activity via intramolecular in-
teraction in vitro (Moskwa et al., 2005). Interestingly, the
present study shows that mutants lacking either IIR 1 (out-
side of BCH) or 2 (within BCH) were still able to suppress
the GAP function in cells. However, when the latter motif
was removed together with the Rho-binding motif, the en-
tire BCH domain became ineffective to suppress the GAP
function. This demonstrated that maximal GAP inhibition
by BCH domain required both RhoA sequestration as well
as autoinhibition mediated by the intramolecular interaction
(Figure 8). Uniquely, such regulation requires the domain
being present in close proximity with the GAP domain in cis
but not in trans because overexpression of BCH as a discrete
entity delinked from the GAP domain does not prevent the
GAP function (Figure 7C). This observation highlights the
importance of concentrating the BCH domain with the GAP
domain to control the local activity of Rho.
In summary, we have provided several lines of evidence
that the adjacent BCH domain on p50RhoGAP could serve
as a local modulator to sequester and prevent RhoA from
being inactivated by the GAP domain. Having both BCH
and GAP domain in close proximity on p50RhoGAP could
also ensure an efﬁcient means for targeting and regulating
Figure 8. Model depicting BCH domain as a
local modulator to sequester RhoA from inactiva-
tion by the adjacent GAP domain and possibly as
a scaffold that links the RhoGAP function to Rho-
GEF and other effectors. The GAP domain of
p50RhoGAP inactivates RhoA and subsequently
induces drastic cytoskeleton collapse and cell
rounding. This cellular effect could be inhibited in
cis by the N-terminal BCH domain, but not its
proline-rich region (PRR), that acts via a concerted
mechanism including the binding of the BCH do-
main to RhoA via its Rho-binding motif (RBM),
thus displacing GAP domain from inhibiting
RhoA, and the intramolecular interaction region 2
(IIR 2) that augments RhoA sequestration to con-
fer complete suppression of the GAP activity
(pathway1).AstheBCHdomaindisplaysdistinc-
tive Rho-binding proﬁle from the GAP domain
and is independent of the nucleotide-binding sta-
tus, it could help ensure that the GTP-bound ac-
tive form of Rho be effectively sequestered from
inactivation by GAP. In addition, independent
BCH domain could also serve as a scaffold that
links RhoGEF (e.g., at least with p115RhoGEF
shown in this study; pathway 2) or interfering
with downstream signaling of RhoA without di-
rectly affecting Rho activity (e.g., abolishing pe-
riphery projections; pathway 3). However, how
thesemultitudemechanismsoperate,eitheriniso-
lation or in concert for a dynamic regulation,
awaits further investigation. See text for details.
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evidence that BCH domain presents a dynamic functional
module for GTPases signaling and therefore calling for fur-
ther investigation on previously unappreciated roles of ho-
mologous BCH domains in other RhoGAPs or RhoGEFs,
some of which are now underway.
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